AR026022A1 - METHOD FOR THE TREATMENT OF OBESITY - Google Patents

METHOD FOR THE TREATMENT OF OBESITY

Info

Publication number
AR026022A1
AR026022A1 ARP000105369A ARP000105369A AR026022A1 AR 026022 A1 AR026022 A1 AR 026022A1 AR P000105369 A ARP000105369 A AR P000105369A AR P000105369 A ARP000105369 A AR P000105369A AR 026022 A1 AR026022 A1 AR 026022A1
Authority
AR
Argentina
Prior art keywords
obesity
treatment
solvatofarma
animal
pharmaceutically acceptable
Prior art date
Application number
ARP000105369A
Other languages
Spanish (es)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9924275.2A external-priority patent/GB9924275D0/en
Priority claimed from GB0001861A external-priority patent/GB0001861D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR026022A1 publication Critical patent/AR026022A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Método para el tratamiento de la obesidad que comprende administrar a un animal que necesite del mismo, un compuesto de formula (1) o una sal o solvatofarmacéuticamente aceptable del mismo. Los métodos para la supresion del apetito, para causarpérdi da de peso, para prevenir el aumento de peso, para afectarpreferencialmente la composicion grasa del cuerpo, para inhibir el antojo del alimento, o para mantener el peso bajo también se describen.Method for the treatment of obesity which comprises administering to an animal in need thereof, a compound of formula (1) or a pharmaceutically acceptable salt or solvatofarma thereof. Methods for appetite suppression, to cause weight loss, to prevent weight gain, to preferentially affect the body's fat composition, to inhibit food cravings, or to keep weight low are also described.

ARP000105369A 1999-10-13 2000-10-12 METHOD FOR THE TREATMENT OF OBESITY AR026022A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9924275.2A GB9924275D0 (en) 1999-10-13 1999-10-13 Method for the treatment of obesity
GB0001861A GB0001861D0 (en) 2000-01-28 2000-01-28 Method for the treatment of obesity

Publications (1)

Publication Number Publication Date
AR026022A1 true AR026022A1 (en) 2002-12-26

Family

ID=26243494

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105369A AR026022A1 (en) 1999-10-13 2000-10-12 METHOD FOR THE TREATMENT OF OBESITY

Country Status (6)

Country Link
EP (1) EP1220673A2 (en)
JP (1) JP2003511410A (en)
AR (1) AR026022A1 (en)
AU (1) AU7750100A (en)
PE (1) PE20010744A1 (en)
WO (1) WO2001026641A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04001165A (en) 2001-08-08 2004-05-20 R Orton Kevin Apparatus and method for electrically conductive weight reduction.
EP3173082A1 (en) * 2002-05-17 2017-05-31 Duke University Method for treating obesity
SI2316456T1 (en) 2003-04-29 2017-10-30 Orexigen Therapeutics, Inc. Compositions for affecting weight loss comprising an opioid antagonist and bupropion
CN101370488B (en) 2005-11-22 2012-07-18 奥雷西根治疗公司 Compositions for increasing insulin sensitivity
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20090090316A (en) 2006-11-09 2009-08-25 오렉시젠 세러퓨틱스 인크. Unit dosage package and methods for administering weight loss medications
CN102026976A (en) * 2007-12-05 2011-04-20 阿斯利康(瑞典)有限公司 Morpholine derivates as antiobesity agents
JP2011521973A (en) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド Methods for treating visceral fat conditions
WO2009147219A1 (en) * 2008-06-04 2009-12-10 Biovitrum Ab (Publ) New compounds vii
BR112012016783A2 (en) 2010-01-11 2015-09-01 Orexigen Therapeutics Inc "Uses of the naltrexone compound or pharmaceutically acceptable salt thereof to bupropion or pharmaceutically acceptable salt thereof or composition thereof and methods for providing therapy"
AU2013271622B2 (en) 2012-06-06 2018-03-01 Nalpropion Pharmaceuticals Llc Methods of treating overweight and obesity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8924528D0 (en) * 1989-10-31 1989-12-20 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use
AU744261B2 (en) * 1997-04-24 2002-02-21 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating eating disorders
AU1403899A (en) * 1997-11-14 1999-06-07 Glaxo Group Limited Method of treating addiction to nicotine products
HUP0100900A3 (en) * 1998-01-21 2002-08-28 Glaxo Group Ltd Pharmaceutically active morpholinol and medicaments containing them
MA26693A1 (en) * 1998-09-28 2004-12-20 Glaxo Group Ltd COMPOSITIONS FOR ORAL ADMINISTRATION

Also Published As

Publication number Publication date
PE20010744A1 (en) 2001-07-23
EP1220673A2 (en) 2002-07-10
AU7750100A (en) 2001-04-23
WO2001026641A3 (en) 2002-01-10
JP2003511410A (en) 2003-03-25
WO2001026641A2 (en) 2001-04-19

Similar Documents

Publication Publication Date Title
AR030933A1 (en) TRIAZOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CO6331425A2 (en) COMPOSITIONS THAT INCLUDE N- (3,4-DIFLUORO-2- (2-FLUORO-4-IODOFENILAMINO) 6-METOXIFENIL) -1- (2,3-DIHYDROXIPROXIPROPIL) CICLOPROPAN-1-SULFAMIDA
DOP2004001052A (en) 11-BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 1 INHIBITORS AMINO
CY1106634T1 (en) THERAPEUTIC DERIVATIVES OF PIPERAZINE
CO5251429A1 (en) DERIVATIVES OF TER-BUTIL- (7-METHYL-IMIDAZO (1,2-A) PIRIDIN-3- IL) -AMINE PROCEDURE FOR PREPARATION, DRUGS THAT CONTAIN THEM, ITS USE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE INHIBITION OF NON-SYNTHEASE AND PHARMACEUTICAL COMPOSITIONS THAT L
PA8591701A1 (en) PIRROLOPIRIMIDINE DERIVATIVES
CY1109242T1 (en) THERAPEUTIC AGENTS USEFUL FOR PAIN TREATMENT
AR026022A1 (en) METHOD FOR THE TREATMENT OF OBESITY
UY26635A1 (en) SYNERGIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
TR200102646T2 (en) Treating eating disorders.
ES2295609T3 (en) TIADIAZOLILPIPERAZINA DERIVATIVES USEFUL TO TREAT OR PREVENT A PAIN.
CY1111951T1 (en) PAINYL-CARBOXAMID COMPOUNDS USEFUL FOR PANTS
BR0314943A (en) Cystic Fibrosis Transmembrane Conductance Regulatory Protein Inhibitors and Uses of These
CO5200778A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES A THERAPEUTICALLY EFFECTIVE AMOUNT OF B ENZIMIDAZOL, ADMINISTERED TO PREVENT AND TREAT CANCER AND INHIBIT METASTASIS
AR039190A1 (en) BENZOFURAN DERIVATIVES, PHARMACEUTICAL COMPOSITION AND MEDICINAL PRODUCT UNDERSTANDING THE COMPOUND
TR200101633T2 (en) Pharmaceutical composition
CL2023000196A1 (en) Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of use thereof
RU2019121690A (en) DEXMEDETOMIDINE OR METHOMIDINE FOR USE FOR THE TREATMENT OF SEPARATION ANXIETY IN DOGS
AR014964A1 (en) DERIVATIVES OF INDOL, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AGENTS TO REDUCE INTRAOCULAR PRESSURE, TREAT GLAUCOMA AND OCULAR HYPERTENSION, USE THE MANUFACTURE OF PHARMACEUTICAL COMPOSITIONS AND PROCEDURE FOR MANUFACTURING OF THESE COMPOSITIONS
AU2002357191A1 (en) Derivatives of isoindigo, indigo and indirubin and use in treating cancer
BR0305708A (en) Benzimidazole derivatives for the treatment of sexual dysfunction
ATE366107T1 (en) USE OF SULFODEHYDROABIETIC ACID TO TREAT INFLAMMATORY BOWEL DISEASE
EA200601249A1 (en) PIPERASINS, SUITABLE FOR THE TREATMENT OF PAIN
RU94045271A (en) Use of 2-phenyl-3-aroylbenzothiophenes for terner's syndrome inhibition
NO912414L (en) RELATIONSHIP WITH MAGIC ACID INHIBITING EFFECT AND PROCEDURE FOR ITS MANUFACTURING.